About Diabetic Retinopathy
Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.
Technavio's analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market.
The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Technavio's report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Bayer
• F. Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals
Other Prominent Vendors
• Actavis
• Alimera Sciences
• Ampio Pharmaceuticals
• Antisense Therapeutics
• BCN Peptides
• Boehringer Ingelheim
• Glycadia
• iCo Therapeutics
• Isis Pharmaceuticals
• Kowa Group
• Lpath
• Numoda Capital
• Ohr Pharmaceutical
• OPKO Health
• Parexel International
• Promedior
• pSivida
• Quark Pharmaceuticals
• R-Tech Ueno
• Sirnaomics
• ThromboGenics
Market Driver
• Growth in patient population
• For a full, detailed list, view our report
Market Challenge
• Availability of effective surgical treatments
• For a full, detailed list, view our report
Market Trend
• Launch of novel agents
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.3 Product Profiles
03.3.1 Lucentis
03.3.2 Eylea
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.2.1 Elevated Blood Glucose
06.2.2 Ischemia
06.2.3 Hypoxia
06.2.4 Neovascularization
06.2.5 Increased Permeability of Retinal Vessels
06.3 Diagnosis
06.3.1 Retinal Photography
06.3.2 Fluorescein Angiography
06.3.3 Optical Coherence Tomography
06.4 Classification
06.4.1 Proliferative Diabetic Retinopathy
06.4.2 Non-proliferative Diabetic Retinopathy
06.5 Epidemiology
06.6 Management
06.6.1 Anti-VEGF Therapy
06.6.2 Intraocular Steroid Injection
06.6.3 Laser Surgery
06.6.4 Vitrectomy
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Key Takeaways
07.4 Five Forces Analysis
08. Pipeline Portfolio
09. Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Corticosteroids
10. Market Segmentation by Route of Administration
10.1 Intravitreal
10.2 Intravenous
11. Geographical Segmentation
11.1 Diabetic Retinopathy Market in Americas
11.1.1 Market Size and Forecast
11.2 Diabetic Retinopathy Market in EMEA
11.2.1 Market Size and Forecast
11.3 Diabetic Retinopathy Market in APAC
11.3.1 Market Size and Forecast
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Novartis
19.2.2 F. Hoffmann-La Roche
19.2.3 Regeneron Pharmaceuticals
19.2.4 Bayer
19.3 Other and Future Prominent Vendors
20. Key Vendor Analysis
20.1 Bayer
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2014
20.1.4 Business Segmentation by Revenue 2013 and 2014
20.1.5 Geographical Segmentation by Revenue 2014
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 F. Hoffmann-La Roche
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Business Strategy
20.2.7 Key Information
20.2.8 SWOT Analysis
20.3 Novartis
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2012 and 2013
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Regeneron Pharmaceuticals
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Product Segmentation
20.4.4 Revenue Product Segmentation
20.4.5 Business Strategy
20.4.6 Key Information
20.4.7 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Development of Diabetic Retinopathy
Exhibit 3: Classification of Diabetic Retinopathy
Exhibit 4: Snapshot of Global Diabetic Retinopathy Market
Exhibit 5: Global Diabetic Retinopathy Market 2014-2019 ($ millions)
Exhibit 6: Key Takeaways: Global Diabetic Retinopathy Market
Exhibit 7: Global Diabetic Retinopathy Market by Type of Molecule
Exhibit 8: Segmentation of Global Diabetic Retinopathy Market by Type of Molecule 2014
Exhibit 9: Global Diabetic Retinopathy Market by Route of Administration
Exhibit 10: Segmentation of Global Diabetic Retinopathy Market by Route of Administration 2014
Exhibit 11: Segmentation of Global Diabetic Retinopathy Market by Geography 2014
Exhibit 12: Segmentation of Global Diabetic Retinopathy Market by Geography 2019
Exhibit 13: Diabetic Retinopathy Market in Americas 2014-2019 ($ millions)
Exhibit 14: Diabetic Retinopathy Market in EMEA 2014-2019 ($ millions)
Exhibit 15: Diabetic Retinopathy Market in APAC 2014-2019 ($ millions)
Exhibit 16: Major Drivers of Global Diabetic Retinopathy Market
Exhibit 17: Major Challenges in Global Diabetic Retinopathy Market
Exhibit 18: Major Trends in Global Diabetic Retinopathy Market
Exhibit 19: Market Share Analysis of Vendors 2014
Exhibit 20: Global Diabetic Retinopathy Market: Revenue by Product 2014
Exhibit 21: Novartis: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
Exhibit 22: Key Takeaways: Novartis
Exhibit 23: F. Hoffmann-La Roche: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
Exhibit 24: Key Takeaways: F. Hoffmann-La Roche
Exhibit 25: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate for Eylea 2011-2014 ($ millions)
Exhibit 26: Key Takeaways: Regeneron Pharmaceuticals
Exhibit 27: Bayer: YoY Revenue and Growth Rate for Eylea 2012-2014 ($ millions)
Exhibit 28: Key Takeaways: Bayer
Exhibit 29: Bayer: Business Segmentation by Revenue 2014
Exhibit 30: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 31: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 32: Business Segmentation of F. Hoffmann-La Roche 2013
Exhibit 33: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 34: F. Hoffmann-La Roche: Pharmaceutical Sales by Geography 2013
Exhibit 35: F. Hoffmann-La Roche: Diagnostics Sales by Geography 2013
Exhibit 36: Novartis: Business Segmentation
Exhibit 37: Novartis: Revenue by Business Segmentation 2013
Exhibit 38: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 39: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 40: Regeneron Pharmaceuticals: Product Segmentation
Exhibit 41: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
